BESOSTAD Tablet

Known hypersensitivity to rabeprazole, other substituted benzimidazoles (e.g. esomeprazole, lansoprazole, omeprazole, pantoprazole), or any ingredient in the formulation.

- The adverse effects reported most often with rabeprazole and other proton pump inhibitors have been headache, diarrhoea, and skin rashes.

- Other effects include pruritus, dizziness, fatigue, constipation, nausea and vomiting, flatulence, abdominal pain, arthralgia and myalgia, urticaria, and dry mouth.

See the package insert about the details below.

- Gastric pH-dependent drugs (e.g. digoxin, ketoconazole)

- Sucralfate

- Warfarin

Pregnancy

There are no adequate and well-controlled studies in pregnant woman. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Lactation

It is unknown whether rabeprazole is distributed into milk; discontinue nursing or drug because of potential risk in nursing infants.

- GI effects: symptomatic response to therapy with rabeprazole does not preclude the occult presence of gastric neoplasm.

- Respiratory effects: administration of proton-pump inhibitors has been associated with an increased risk for developing certain infections (e.g. community-acquired pneumonia).

Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+K+ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide.